
To evaluate the zzso safety, and zzso of combination therapy with intramuscular zzso zzso and oral zzso a potent inhibitor of zzso zzso in patients with zzso multiple sclerosis zzso having breakthrough disease zzso 

zzso zzso zzso 

Louisiana State University Health Sciences Center, zzso 

Fifteen patients with zzso taking zzso zzso with breakthrough disease activity took zzso for 4 zzso Patients underwent monthly zzso examination, magnetic resonance imaging of the brain using zzso zzso and safety blood zzso 

zzso treatment with intramuscular zzso zzso plus oral zzso 100 zzso daily, for 4 zzso 

The primary end point was zzso zzso number change, and the secondary end points were zzso rates, safety and zzso of the combination of zzso zzso and zzso in patients with zzso Expanded zzso zzso zzso score, serum zzso zzso levels, and zzso migration of zzso exposed to serum from patients with zzso 

Combination of zzso and zzso zzso treatment resulted in reductions in zzso zzso numbers and zzso Expanded zzso zzso zzso values zzso zzso zzso for zzso Only 1 patient zzso zzso analyses indicated correlations between decreased serum zzso zzso levels and enhancing zzso activity zzso zzso migration of zzso incubated with serum from patients with zzso undergoing combination therapy was zzso zzso effects were zzso no adverse synergistic effects of combination therapy or unexpected adverse events were zzso 

Combination of intramuscular zzso zzso and oral zzso treatment was effective, safe, and well zzso Controlled clinical trials in larger zzso of patients with zzso are needed to evaluate the efficacy and zzso of this zzso Trial Registration zzso zzso zzso 

